MOCLOBEMIDE AND SPECIFIC SEROTONIN REUPTAKE INHIBITOR COMBINATION TREATMENT OF RESISTANT ANXIETY AND DEPRESSIVE-DISORDERS
MOCLOBEMIDE AND SPECIFIC SEROTONIN REUPTAKE INHIBITOR COMBINATION TREATMENT OF RESISTANT ANXIETY AND DEPRESSIVE-DISORDERS
复制标题
DOI：
10.1002/hup.470100205
复制
发表时间：
1995-03-01
影响因子：
1.7
通讯作者：
BASHIR, F
中科院分区：
文献类型：
--
作者：
BAKISH, D;HOOPER, CL;BASHIR, F
这项回顾性研究的目的是确定吗氯贝胺，一种特异性和可逆的单胺氧化酶-A抑制剂(RIMA)，在临床环境中与特异性5-羟色胺再摄取抑制剂(SSRIs)联合使用时，是如何有效和安全的。对我们中心所有接受吗氯贝胺和SSRI联合治疗的情感性和焦虑症患者进行了全面的图表审查。吗氯贝胺-SSRI联合治疗耐药患者有较好疗效。联合治疗耐受性良好，药物相互作用很少。剂量应从低开始，缓慢而仔细地滴定，并应密切监测患者。
This retrospective study was undertaken with the objective of determining how effective and safe moclobemide, a specific and reversible inhibitor of monoamine oxidase-A (RIMA), is when used in combination with specific serotonin re-uptake inhibitors (SSRIs), in a clinical setting. A thorough chart review was done of all patients with affective and anxiety disorders seen at our centre who received combination treatment with moclobemide and an SSRI. Combination moclobemide-SSRI treatment demonstrated good efficacy in treating treatment-resistant patients. The combination treatment was well tolerated with very few drug interactions. Dosages should be started low, titrated slowly and carefully, and patients should be monitored closely.